Yongzhuo Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/989557/publications.pdf

Version: 2024-02-01

138 papers 8,362 citations

47 h-index

46918

85 g-index

148 all docs

148 docs citations

148 times ranked

11538 citing authors

#	Article	IF	CITATIONS
1	Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles. Acta Pharmaceutica Sinica B, 2022, 12, 1523-1533.	5.7	25
2	Remodeling "cold―tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona. Acta Pharmaceutica Sinica B, 2022, 12, 2057-2073.	5.7	24
3	Nanotherapeutic macrophage-based immunotherapy for the peritoneal carcinomatosis of lung cancer. Nanoscale, 2022, 14, 2304-2315.	2.8	8
4	Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants. Acta Pharmaceutica Sinica B, 2022, 12, 3187-3194.	5.7	11
5	A drug-free nanozyme for mitigating oxidative stress and inflammatory bowel disease. Journal of Nanobiotechnology, 2022, 20, 107.	4.2	24
6	Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity. Frontiers in Pharmacology, 2022, 13, 840440.	1.6	6
7	Brain-targeting biomimetic nanoparticles for codelivery of celastrol and LY2157299 for reversing glioma immunosuppression. International Journal of Pharmaceutics, 2022, 619, 121709.	2.6	12
8	Anti-alcoholism drug disulfiram for targeting glioma energy metabolism using BBB-penetrating delivery of fixed-dose combination. Nano Today, 2022, 44, 101448.	6.2	12
9	Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents. Molecules, 2022, 27, 3836.	1.7	2
10	Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy. Acta Pharmacologica Sinica, 2021, 42, 1516-1523.	2.8	23
11	Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. Journal of Controlled Release, 2021, 329, 1249-1261.	4.8	27
12	Biomimetic camouflage delivery strategies for cancer therapy. Nanoscale, 2021, 13, 8693-8706.	2.8	19
13	Magnetism-mediated targeting hyperthermia-immunotherapy in "cold―tumor with CSF1R inhibitor. Theranostics, 2021, 11, 6860-6872.	4.6	36
14	Teaching new tricks to old dogs: A review of drug repositioning of disulfiram for cancer nanomedicine. View, 2021, 2, 20200127.	2.7	14
15	Genetically-engineered "all-in-one―vaccine platform for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 3622-3635.	5.7	9
16	Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment. Nano Today, 2021, 40, 101244.	6.2	16
17	Disulfiram-loaded lactoferrin nanoparticles for treating inflammatory diseases. Acta Pharmacologica Sinica, 2021, 42, 1913-1920.	2.8	33
18	Remodeling immune microenvironment in periodontitis using resveratrol liposomes as an antibiotic-free therapeutic strategy. Journal of Nanobiotechnology, 2021, 19, 429.	4.2	19

#	Article	IF	Citations
19	Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer. Applied Materials Today, 2020, 18, 100492.	2.3	29
20	A Trojan horse biomimetic delivery strategy using mesenchymal stem cells for PDT/PTT therapy against lung melanoma metastasis. Biomaterials Science, 2020, 8, 1160-1170.	2.6	52
21	Advances on Tumor-Targeting Delivery of Cytotoxic Proteins. ACS Pharmacology and Translational Science, 2020, 3, 107-118.	2.5	18
22	Lactoferrin-mediated macrophage targeting delivery and patchouli alcohol-based therapeutic strategy for inflammatory bowel diseases. Acta Pharmaceutica Sinica B, 2020, 10, 1966-1976.	5.7	46
23	Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomaterials Science, 2020, 8, 7166-7176.	2.6	11
24	Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery., 2020, 8, e000207.		70
25	BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR ^{T790M} mutation. Theranostics, 2020, 10, 6122-6135.	4.6	52
26	Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery. Biomaterials, 2020, 255, 120187.	5.7	72
27	Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy. Frontiers in Cell and Developmental Biology, 2020, 8, 400.	1.8	21
28	Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer. , 2020, , 173-198.		1
29	Macrophage-based nanotherapeutic strategies in ulcerative colitis. Journal of Controlled Release, 2020, 320, 363-380.	4.8	82
30	Introduction to biomimetic therapeutics. Biomaterials Science, 2020, 8, 1017-1019.	2.6	0
31	Combination therapy based on nano codelivery for overcoming cancer drug resistance. Medicine in Drug Discovery, 2020, 6, 100024.	2.3	66
32	Recent progress in drug delivery. Acta Pharmaceutica Sinica B, 2019, 9, 1145-1162.	5.7	529
33	Menthol-modified BSA nanoparticles for glioma targeting therapy using an energy restriction strategy. NPG Asia Materials, 2019, 11 , .	3.8	24
34	TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacologica Sinica, 2019, 40, 1373-1385.	2.8	42
35	Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery <i>via</i> a SHEATH strategy. Nanoscale, 2019, 11, 611-621.	2.8	18
36	Trained Macrophage Bioreactor for Penetrating Delivery of Fused Antitumor Protein. ACS Applied Materials & Samp; Interfaces, 2019, 11, 23018-23025.	4.0	8

#	Article	IF	CITATIONS
37	Nano-Structural Effects on Gene Transfection: Large, Botryoid-Shaped Nanoparticles Enhance DNA Delivery via Macropinocytosis and Effective Dissociation. Theranostics, 2019, 9, 1580-1598.	4.6	22
38	Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination. Journal of Gene Medicine, 2019, 21, e3089.	1.4	19
39	Reprogramming Tumor Immune Microenvironment (TIME) and Metabolism via Biomimetic Targeting Codelivery of Shikonin/JQ1. Nano Letters, 2019, 19, 2935-2944.	4.5	134
40	Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin \hat{l}^2 3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics, 2019, 9, 265-278.	4.6	141
41	The intra-brain distribution of brain targeting delivery systems. , 2019, , 409-438.		7
42	Macrophage-Membrane-Coated Nanoparticles for Tumor-Targeted Chemotherapy. Nano Letters, 2018, 18, 1908-1915.	4.5	289
43	Liposomal Codelivery of Doxorubicin and Andrographolide Inhibits Breast Cancer Growth and Metastasis. Molecular Pharmaceutics, 2018, 15, 1618-1626.	2.3	49
44	Dual-targeting biomimetic delivery for anti-glioma activity <i>via</i> remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chemical Science, 2018, 9, 2674-2689.	3.7	196
45	Improved method for synthesis of low molecular weight protamine–siRNA conjugate. Acta Pharmaceutica Sinica B, 2018, 8, 116-126.	5.7	20
46	Targeting death receptors for drug-resistant cancer therapy: Codelivery of pTRAIL and monensin using dual-targeting and stimuli-responsive self-assembling nanocomposites. Biomaterials, 2018, 158, 56-73.	5.7	57
47	A novel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver. Nano Research, 2018, 11, 4507-4523.	5.8	17
48	Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation. Acta Pharmaceutica Sinica B, 2018, 8, 74-84.	5.7	70
49	Cell-penetrating peptide-based non-invasive topical delivery systems. Journal of Pharmaceutical Investigation, 2018, 48, 77-87.	2.7	21
50	Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers. ACS Applied Materials & Samp; Interfaces, 2018, 10, 41118-41128.	4.0	109
51	The Endotoxin Delivery Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. Immunity, 2018, 49, 740-753.e7.	6.6	377
52	Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery. Acta Pharmaceutica Sinica B, 2018, 8, 956-968.	5.7	38
53	Remodeling Tumorâ€Associated Macrophages and Neovascularization Overcomes EGFR ^{T790M} â€Associated Drug Resistance by PD‣1 Nanobodyâ€Mediated Codelivery. Small, 2018 14, e1802372.	8,5.2	60
54	Smart Cell-Penetrating Peptide-Based Techniques for Intracellular Delivery of Therapeutic Macromolecules. Advances in Protein Chemistry and Structural Biology, 2018, 112, 183-220.	1.0	18

#	Article	IF	CITATIONS
55	Roles of Albuminâ€Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery. ChemBioChem, 2018, 19, 1796-1805.	1.3	57
56	Natural Brain Penetration Enhancer-Modified Albumin Nanoparticles for Glioma Targeting Delivery. ACS Applied Materials & Delivery. 10, 30201-30213.	4.0	47
57	Antiglioma via regulating oxidative stress and remodeling tumor-associated macrophage using lactoferrin-mediated biomimetic codelivery of simvastatin/fenretinide. Journal of Controlled Release, 2018, 287, 12-23.	4.8	49
58	Improved Protein Toxin Delivery Based on ATTEMPTS Systems. Current Drug Targets, 2018, 19, 380-392.	1.0	11
59	Poly- \hat{l}^3 -glutamic acid-based GGT-targeting and surface camouflage strategy for improving cervical cancer gene therapy. Journal of Materials Chemistry B, 2017, 5, 1315-1327.	2.9	23
60	Albumin Biomimetic Nanocorona Improves Tumor Targeting and Penetration for Synergistic Therapy of Metastatic Breast Cancer. Advanced Functional Materials, 2017, 27, 1605679.	7.8	73
61	Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance. Molecular Pharmaceutics, 2017, 14, 1429-1438.	2.3	39
62	Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Acta Pharmacologica Sinica, 2017, 38, 885-896.	2.8	87
63	Microneedle-Assisted, DC-Targeted Codelivery of pTRP-2 and Adjuvant of Paclitaxel for Transcutaneous Immunotherapy. Small, 2017, 13, 1700666.	5.2	50
64	Cancer nanobiotechnolgy. Acta Pharmacologica Sinica, 2017, 38, 735-737.	2.8	4
65	Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment. International Journal of Pharmaceutics, 2017, 524, 101-110.	2.6	12
66	Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols. Molecular Pharmaceutics, 2017, 14, 3473-3479.	2.3	20
67	Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis. ACS Applied Materials & Emp; Interfaces, 2017, 9, 26648-26664.	4.0	86
68	A mannosylated PEI–CPP hybrid for TRAIL gene targeting delivery for colorectal cancer therapy. Polymer Chemistry, 2017, 8, 5275-5285.	1.9	27
69	Dualâ€Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drugâ€Resistant Cancer Therapy. Advanced Functional Materials, 2017, 27, 1700403.	7.8	118
70	Reprogramming Tumor-Associated Macrophages To Reverse EGFR ^{T790M} Resistance by Dual-Targeting Codelivery of Gefitinib/Vorinostat. Nano Letters, 2017, 17, 7684-7690.	4.5	90
71	Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature. Biomaterials, 2017, 116, 57-68.	5.7	57
72	Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1. Frontiers in Pharmacology, 2017, 8, 325.	1.6	45

#	Article	IF	Citations
73	High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA. Theranostics, 2017, 7, 2495-2508.	4.6	40
74	Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery. Theranostics, 2017, 7, 3489-3503.	4.6	43
75	Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. Nanotheranostics, 2017, 1, 114-130.	2.7	10
76	Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biology and Medicine, 2017, 14, 212.	1.4	98
77	Fusogenic Reactive Oxygen Species Triggered Chargeâ€Reversal Vector for Effective Gene Delivery. Advanced Materials, 2016, 28, 1743-1752.	11.1	288
78	Gene Delivery: Fusogenic Reactive Oxygen Species Triggered Chargeâ€Reversal Vector for Effective Gene Delivery (Adv. Mater. 9/2016). Advanced Materials, 2016, 28, 1714-1714.	11.1	11
79	Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharmaceutica Sinica B, 2016, 6, 352-358.	5.7	59
80	Blood–Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery <i>via</i> Albumin-Binding Protein Pathways for Antiglioma Therapy. ACS Nano, 2016, 10, 9999-10012.	7.3	384
81	Dual-Targeting Magnetic PLGA Nanoparticles for Codelivery of Paclitaxel and Curcumin for Brain Tumor Therapy. ACS Applied Materials & Interfaces, 2016, 8, 32159-32169.	4.0	184
82	Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity. Pharmaceutical Research, 2016, 33, 2218-2228.	1.7	24
83	Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer. Acta Pharmacologica Sinica, 2016, 37, 1110-1120.	2.8	21
84	Intracellularly Acid-Switchable Multifunctional Micelles for Combinational Photo/Chemotherapy of the Drug-Resistant Tumor. ACS Nano, 2016, 10, 3496-3508.	7.3	267
85	Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization. Polymer Chemistry, 2015, 6, 373-379.	1.9	45
86	Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (\hat{l}^2 -amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials, 2015, 48, 1-15.	5.7	134
87	Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma. Molecular Pharmaceutics, 2015, 12, 922-931.	2.3	82
88	PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study. Pharmaceutical Research, 2015, 32, 2690-703.	1.7	24
89	A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging. Theranostics, 2015, 5, 787-795.	4.6	61
90	Green synthesis of hyaluronic acid-based silver nanoparticles and their enhanced delivery to CD44 ⁺ cancer cells. RSC Advances, 2015, 5, 43733-43740.	1.7	30

#	Article	IF	Citations
91	Bioreducible Micelles with Endosomal Buffering and Multidrug Resistance-Reversing Function Enhance Anti-Tumor Efficacy of Doxorubicin. Journal of Biomedical Nanotechnology, 2015, 11, 1764-1775.	0.5	6
92	Hydrothermal Synthesis and Biocompatibility Study of Highly Crystalline Carbonated Hydroxyapatite Nanorods. Nanoscale Research Letters, 2015, 10, 1018.	3.1	48
93	Recombinant TAT-gelonin fusion toxin: Synthesis and characterization of heparin/protamine-regulated cell transduction. Journal of Biomedical Materials Research - Part A, 2015, 103, 409-419.	2.1	26
94	Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors. Advanced Drug Delivery Reviews, 2015, 81, 142-160.	6.6	208
95	Epirubicin-Loaded Superparamagnetic Iron-Oxide Nanoparticles for Transdermal Delivery: Cancer Therapy by Circumventing the Skin Barrier. Small, 2015, 11, 239-247.	5.2	73
96	Editorial (Thematic Issue: "Cell-penetrating Peptides and Drug Deliveryâ€). Current Pharmaceutical Biotechnology, 2014, 15, 191-191.	0.9	4
97	Molecularâ€Dynamicsâ€Simulationâ€Driven Design of a Proteaseâ€Responsive Probe for Inâ€Vivo Tumor Imaging Advanced Materials, 2014, 26, 8174-8178.	11.1	26
98	Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. Molecular Pharmaceutics, 2014, 11, 2600-2611.	2.3	72
99	Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer. Journal of Controlled Release, 2014, 192, 47-56.	4.8	93
100	Drug Delivery and Reversal of MDR. Molecular Pharmaceutics, 2014, 11, 2493-2494.	2.3	8
101	Cell-Penetrating Apoptotic Peptide/p53 DNA Nanocomplex as Adjuvant Therapy for Drug-Resistant Breast Cancer. Molecular Pharmaceutics, 2014, 11, 3352-3360.	2.3	35
102	Co-delivery of doxorubicin and RNA using pH-sensitive poly (\hat{l}^2 -amino ester) nanoparticles for reversal of multidrug resistance of breast cancer. Biomaterials, 2014, 35, 6047-6059.	5.7	113
103	Proteaseâ€Activatable Hybrid Nanoprobe for Tumor Imaging. Advanced Functional Materials, 2014, 24, 5443-5453.	7.8	26
104	CPP-mediated Protein Delivery in a Noncovalent Form: Proof-of-Concept for Percutaneous and Intranasal Delivery. Protein and Peptide Letters, 2014, 21, 1129-1136.	0.4	12
105	Cell-Penetrating Peptide-Mediated Topical Delivery of Biomacromolecular Drugs. Current Pharmaceutical Biotechnology, 2014, 15, 231-239.	0.9	18
106	Cell-penetrating peptide-modified PLGA nanoparticles for enhanced nose-to-brain macromolecular delivery. Macromolecular Research, 2013, 21, 435-441.	1.0	47
107	Cell-penetrating albumin conjugates for enhanced doxorubicin delivery. Polymer Chemistry, 2013, 4, 4584.	1.9	27
108	Template synthesis of PMAA@chitosan hollow nanorods for docetaxel delivery. Polymer Chemistry, 2013, 4, 2489.	1.9	10

#	Article	IF	CITATIONS
109	Coâ€delivery of Cellâ€permeable Chimeric Apoptosis AVPIR ₈ Peptide/p53 DNA for Cocktail Therapy. Advanced Functional Materials, 2013, 23, 6068-6075.	7.8	15
110	The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials, 2013, 34, 7733-7743.	5.7	59
111	Pluronic L61 as a long-circulating modifier for enhanced liposomal delivery of cancer drugs. Polymer Chemistry, 2013, 4, 2958.	1.9	14
112	Ultrasound-mediated targeted microbubbles: a new vehicle for cancer therapy. Frontiers of Chemical Science and Engineering, 2013, 7, 20-28.	2.3	6
113	Overcoming oral insulin delivery barriers: application of cell penetrating peptide and silica-based nanoporous composites. Frontiers of Chemical Science and Engineering, 2013, 7, 9-19.	2.3	20
114	Curb challenges of the "Trojan Horse―approach: Smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Advanced Drug Delivery Reviews, 2013, 65, 1299-1315.	6.6	175
115	Magnetic Nanoparticles for Tumor Imaging and Therapy: A So-Called Theranostic System. Pharmaceutical Research, 2013, 30, 2445-2458.	1.7	45
116	Magnetic Nanoparticles for MRI of Brain Tumors. Current Pharmaceutical Biotechnology, 2012, 13, 2403-2416.	0.9	35
117	Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery. Journal of Materials Chemistry, 2012, 22, 10029.	6.7	25
118	An injectable hybrid nanoparticle-in-oil-in-water submicron emulsion for improved delivery of poorly soluble drugs. Nanoscale Research Letters, 2012, 7, 219.	3.1	10
119	TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials, 2012, 33, 6155-6161.	5.7	182
120	In vivo delivery of cell-permeable antisense hypoxia-inducible factor $1\hat{l}\pm$ oligonucleotide to adipose tissue reduces adiposity in obese mice. Journal of Controlled Release, 2012, 161, 1-9.	4.8	26
121	Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. Journal of Controlled Release, 2012, 161, 884-892.	4.8	91
122	An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics. Soft Matter, 2011, 7, 5873.	1,2	22
123	Low molecular weight protamine/insulin formulation with potential to attenuate protamine-masqueraded insulin allergy. Macromolecular Research, 2011, 19, 1224-1226.	1.0	7
124	Polysorbate cationic synthetic vesicle for gene delivery. Journal of Biomedical Materials Research - Part A, 2011, 96A, 513-519.	2.1	35
125	Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex nanoparticles. International Journal of Pharmaceutics, 2011, 405, 188-195.	2.6	15
126	ATTEMPTS System: A Macromolecular Prodrug Strategy for Cancer Drug Delivery. Current Pharmaceutical Design, 2010, 16, 2369-2376.	0.9	35

#	Article	lF	CITATION
127	Alginate–Chitosan–PLGA Composite Microspheres Enabling Single-Shot Hepatitis B Vaccination. AAPS Journal, 2010, 12, 519-524.	2.2	30
128	Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials, 2010, 31, 9086-9091.	5.7	172
129	Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1α-oligonucleotide. Journal of Controlled Release, 2010, 144, 82-90.	4.8	20
130	Synthetic Skinâ€Permeable Proteins Enabling Needleless Immunization. Angewandte Chemie - International Edition, 2010, 49, 2724-2727.	7.2	47
131	The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials, 2010, 31, 5842-5848.	5.7	67
132	The artificial peroxidase activity of magnetic iron oxide nanoparticles and its application to glucose detection. Biomaterials, 2009, 30, 4716-4722.	5.7	274
133	PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. Journal of Materials Science: Materials in Medicine, 2008, 19, 607-614.	1.7	68
134	The ATTEMPTS delivery systems for macromolecular drugs. Expert Opinion on Drug Delivery, 2008, 5, 1255-1266.	2.4	20
135	A hybrid thermo-sensitive chitosan gel for sustained release of Meloxicam. Journal of Biomaterials Science, Polymer Edition, 2008, 19, 1239-1247.	1.9	16
136	Glioma selectivity of magnetically targeted nanoparticles: A role of abnormal tumor hydrodynamics. Journal of Controlled Release, 2007, 122, 315-323.	4.8	80
137	Cationic liposomes modified with non-ionic surfactants as effective non-viral carrier for gene transfer. Colloids and Surfaces B: Biointerfaces, 2006, 49, 158-164.	2.5	31
138	Preparation and Characterization of Liposomes Encapsulating Chitosan Nanoparticles. Biological and Pharmaceutical Bulletin, 2005, 28, 387-390.	0.6	39